Intestinal fungi and antifungal secretory immunoglobulin A in Crohn's disease

The human gastrointestinal tract harbors trillions of commensal microorganisms. Emerging evidence points to a possible link between intestinal fungal dysbiosis and antifungal mucosal immunity in inflammatory bowel disease, especially in Crohn's disease (CD). As a protective factor for the gut m...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2023-06, Vol.14, p.1177504-1177504
Main Authors: Sun, Meng, Ju, Jingyi, Xu, Hongzhen, Wang, Yufang
Format: Article
Language:English
Subjects:
Antifungal Agents - therapeutic use
antifungal immunity
Crohn Disease - microbiology
Crohn’s disease
Dysbiosis - microbiology
Fungi
Humans
Immunoglobulin A, Secretory
Immunology
intestinal fungi
mucosal immunity
secretory IgA (SIgA)
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The human gastrointestinal tract harbors trillions of commensal microorganisms. Emerging evidence points to a possible link between intestinal fungal dysbiosis and antifungal mucosal immunity in inflammatory bowel disease, especially in Crohn's disease (CD). As a protective factor for the gut mucosa, secretory immunoglobulin A (SIgA) prevents bacteria from invading the intestinal epithelium and maintains a healthy microbiota community. In recent years, the roles of antifungal SIgA antibodies in mucosal immunity, including the regulation of intestinal immunity binding to hyphae-associated virulence factors, are becoming increasingly recognized. Here we review the current knowledge on intestinal fungal dysbiosis and antifungal mucosal immunity in healthy individuals and in patients with CD, discuss the factors governing antifungal SIgA responses in the intestinal mucosa in the latter group, and highlight potential antifungal vaccines targeting SIgA to prevent CD.
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2023.1177504